The role of progesterone and the progesterone receptor in cancer

References

• Graham DJ, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18(4):502–519.
   PubMed Web of Science ®Google Scholar
• Fernandez-Valdivia R, Mukherjee A, Mulac-Jericevic B, et al. Revealing progesterone’s role in uterine and mammary gland biology: insights from the mouse. Semin Reprod Med. 2005;23:22–37.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gustafsson JA. Progesterone receptor-estrogen receptor crosstalk: a novel insight. Trends Endocrin Met. 2015;26(9):453–454.
   PubMed Web of Science ®Google Scholar
• Tsai SY, Carlstedt-Duke J, Weigel NL, et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell. 1988;55(2):361–369.
   PubMed Web of Science ®Google Scholar
• Richer JK, Lange CA, Manning NG, et al. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem. 1998;273(47):31317–31326.
   PubMed Web of Science ®Google Scholar
• Hilton HN, Graham D, Clarke CL. Minireview: progesterone regulation of proliferation in the normal human breast and in breast cancer: a tale of two scenarios. Mol Endocrinol. 2015;29(9):1230–1242.
   PubMed Web of Science ®Google Scholar
• Daniel AR, Faivre EJ, Lange CA. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol. 2007;21(12):2890–2906.
   PubMed Web of Science ®Google Scholar
• Weigel NL, Bai W, Zhang Y, et al. Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol. 1995;53(1–6):509–514.
   PubMed Web of Science ®Google Scholar
• Abdel-Hafiz H, Takimoto GS, Tung L, et al. The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem. 2002;277(37):33950–33956.
   PubMed Web of Science ®Google Scholar
• Friedman LS, Ostermeyer EA, Lynch ED, et al. The search for BRCA1. Cancer Res. 1994;54:6374–6382.
   PubMed Web of Science ®Google Scholar
• Zheng L, Annab LA, Afshari CA, et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA. 2001;98:9587–9592.
   PubMed Web of Science ®Google Scholar
• Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999;284:1354–1356.
   PubMed Web of Science ®Google Scholar
• Ma Y, Katiyar P, Jones LP, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2006;20:14–34.
   PubMed Web of Science ®Google Scholar
• Calvo V, Beato M. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res. 2011;71:3422–3431.
   PubMed Web of Science ®Google Scholar
• Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011;6(3):359–369.
   PubMedGoogle Scholar
• Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523:313–317.
   PubMed Web of Science ®Google Scholar
• Azeez JM, Sithul H, Hariharan I, et al. Progesterone regulates the proliferation of breast cancer cells – in vitro evidence. Drug Des Devel Ther. 2015;9:5987–5999.
   PubMed Web of Science ®Google Scholar
• Badwe R, Hawaldar R, Parmar V, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol. 2011;29:2845–2851.
   PubMed Web of Science ®Google Scholar
• Zheng ZY, Bay BH, Aw SE, et al. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J Biol Chem. 2005;280:17480–17487.
   PubMed Web of Science ®Google Scholar
• Vignon F, Cardon S, Chalbos D, et al. Antiestrogenic effect of R5020, a synthetic progestin, in human breast cancer cells in culture. J Clin Endocrinol Meetab. 1983;56:1124–1130.
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Swarbrick A, Lee CS, et al. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol. 1998;18:1812–1825.
   PubMed Web of Science ®Google Scholar
• Chen CC, Hardy DB, Mendelson CR. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1). J Biol Chem. 2011;286:43091–43102.
   PubMed Web of Science ®Google Scholar
• Kabos P, Finlay-Schultz J, Li C, et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012;135:415–432.
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979.
   PubMed Web of Science ®Google Scholar
• Pichon MF, Pallud C, Brunet M, et al. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980;40:3357–3360.
   PubMed Web of Science ®Google Scholar
• Bines J, Dienstmann R, Obadia RM, et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann Oncol. 2014;25:831–836.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids. 2014;90:53–59.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19:2496–2502.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesis-generating study. J Clin Oncol. 2005;23:7512–7517.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Gorsski J. Estrogen-induced transcription of the progesterone receptor gene does not parallel estrogen receptor occupancy. Proc Natl Acad Sci USA. 1996;93:15180–15184.
   PubMed Web of Science ®Google Scholar
• Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-1 inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17(4):575–588.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Yeates C, Balleine RL, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 1995;55(21):5063–5068.
   PubMed Web of Science ®Google Scholar
• Mote PA, Bartow S, Tran N, et al. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2001;72(2):163–172.
   Web of Science ®Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427.
   PubMed Web of Science ®Google Scholar
• Beral V, Reeves G, Bull D. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. Jama. 2003;289:3243–3253.
   PubMed Web of Science ®Google Scholar
• Charlton BM, Rich-Edwards JW, Colditz GA, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. Bmj. 2014;349:g6356.
   PubMed Web of Science ®Google Scholar
• Booth BW, Smith GH. Estrogen receptor-α and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res. 2006;8:R49.
   PubMed Web of Science ®Google Scholar
• Brisken C, Duss S. Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev. 2007;3(2):147–156.
   PubMed Web of Science ®Google Scholar
• Harmes DC, DiRenzo J. Cellular quiescence in mammary stem cells and breast tumor stem cells: got testable hypotheses? J Mammary Gland Biol Neoplasia. 2009;14(1):19–27.
   PubMed Web of Science ®Google Scholar
• Clarke RB, Spence K, Anderson E, et al. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol. 2005;277:443–456.
   PubMed Web of Science ®Google Scholar
• Klijin JG, De Jong FH, Bakker GH, et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989;49:2851–2856.
   PubMed Web of Science ®Google Scholar
• Ramieu G, Maudelonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bulletin Du Cancer. 1987;74:455–461.
   PubMed Web of Science ®Google Scholar
• Klijin JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000;65:825–830.
   PubMed Web of Science ®Google Scholar
• Perrault D, Eisenhauer EA, Pritchaard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 1996;14:2709–2712.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999;35:214–218.
   PubMed Web of Science ®Google Scholar
• Jonat W, Bachelot T, Ruhstaller T, et al. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013;24(10):2543–2548.
   PubMed Web of Science ®Google Scholar
• Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22(4):145–152.
   PubMed Web of Science ®Google Scholar
• Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–1149.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278–3285.
   PubMed Web of Science ®Google Scholar
• Carlson MJ, Thiel KW, Yang S, et al. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discovery Med. 2012;14(76):215–222.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Haldorsen IS, Trovik J. Markers for individualized therapy in endometrial carcinoma. Lancet Oncol. 2012;13(8):e353–361.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Gong C, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015;13:208–219.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol. 1999;17:1736–1744.
   PubMed Web of Science ®Google Scholar
• Singh M, Zaino RJ, Viliaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2007;106:325–333.
   PubMed Web of Science ®Google Scholar
• Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798–2803.
   PubMed Web of Science ®Google Scholar
• Guy MS, Qamar L, Behbakht K, et al. Progestin treatment decreases CD133+ cancer stem cell population in endometrial cancer. Gynecol Onc. 2016;140:518–526.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang F, Zhang W, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23(1):25–33.
   PubMed Web of Science ®Google Scholar
• Yu Y, Lee JS, Xie N, et al. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 2014;9:e92714.
   PubMed Web of Science ®Google Scholar
• Yu Y, Yang O, Fazli L, et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate. 2015;75:1043–1050.
   PubMed Web of Science ®Google Scholar
• Vannucchi G, De Leo S, Perrino M. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. Eur J Endocrin. 2015;173:29–36.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Moravek MB, Yin P, et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33:357–365.
   PubMed Web of Science ®Google Scholar
• Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999;14(11):2844–2850.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433–2442.
   PubMed Web of Science ®Google Scholar
• Murphy AA, Kettel LM, Morales AJ. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76(2):513–517.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–420.
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Cohen R, et al. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res. 2010;30:623–628.
   PubMed Web of Science ®Google Scholar
• Check JH, Cohen R. The role of progesterone and the progesterone receptor in human reproduction and cancer. Expert Rev Endocrinol Metab. 2013;8:469–484.
   PubMedGoogle Scholar
• Szekeres-Bartho J, Polgar B. PIBF: the double edged sword. Pregnancy and tumor. Am J Reprod Immunol. 2010;64:77–86.
   PubMed Web of Science ®Google Scholar
• Polgar B, Kispal GY, Lachmann M, et al. Molecular cloning and immunological characterization of a novel cDNA coding for PIBF. J Immunol. 2003;171:5956–5963.
   PubMed Web of Science ®Google Scholar
• Faust Z, Laskarin G, Rukavina D, et al. Progesterone-induced blocking factor inhibits degranulation of NK cells. Am J Reprod Immunol. 1999;42:71.
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alers the Th1/Th2 balance. J Reprod Immunol. 1996;31:81–95.
   PubMed Web of Science ®Google Scholar
• Lachmann M, Gelbmann D, Kalman E, et al. PIBF (progesterone-induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer. 2004;112:51–60.
   PubMed Web of Science ®Google Scholar
• Rozenblum E, Vahteristo P, Sandberg T, et al. A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. Hum Genet. 2002;110:111–121.
   PubMed Web of Science ®Google Scholar
• Srivastava MD, Thomas A, Srivastava BI, et al. Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007;48:1610–1617.
   PubMed Web of Science ®Google Scholar
• Kyurkchiev D, Naydenov E, Tumangelova-Yuzeir K, et al. Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol. 2014;34(4):479–489.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Arenas A, Valadez-Cosmes P, Kimenez-Arellano C, et al. Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway. J Steroid Biochem Mol Biol. 2014;1`44:Pt B:463-470.
   Google Scholar
• Kim K, Rhee K. The pericentriolar satellite protein CeP90 is crucial for integrity of the mitotic spindle pole. J Cell Sci. 2011;124:338–347.
   PubMed Web of Science ®Google Scholar
• Halasz M, Polgar B, Berta G, et al. Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity. Cell Mol Life Sci. 2013;70:4617–4630.
   PubMed Web of Science ®Google Scholar
• Kozma N, Halasz M, Polgar B, et al. Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor. J Immunol. 2006;176(2):819–826.
   PubMed Web of Science ®Google Scholar
• Check JH, SanSoucie L, Chern J, et al. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity. Clin Exp Obst Gynecol. 2007;34:207–211.
   PubMed Web of Science ®Google Scholar
• Schneider CC, Gibb RK, Taylor DD, et al. Inhibition of endometrial cancer cell lines by mifepristone (ru 486). J Soc Gynecol Investig. 1996;5:334–338.
   Google Scholar
• Poole AJ, Li Y, Kim Y, et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314:1467–1470.
   PubMed Web of Science ®Google Scholar
• El Etreby MF, Liang Y, Johnson MH, et al. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate. 2000;42:99–106.
   PubMed Web of Science ®Google Scholar
• Rose FV, Barnea ER. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene. 1996;12:999–1003.
   PubMed Web of Science ®Google Scholar
• Li DQ, Wang ZB, Bai J, et al. Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol. 2004;10:2628–2631.
   PubMed Web of Science ®Google Scholar
• Check JH, Sansoucie L, Chern J, et al. Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res. 2009;29(8):2977–2980.
   PubMed Web of Science ®Google Scholar
• Check JH, Sansoucie L, Chern J, et al. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010;30:119–122.
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Wilson C, et al. Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies. Anticancer Res. 2010;30:4921–4924.
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Sansoucie L, et al. Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon – case report. Anticancer Res. 2009;29(5):1611–1613.
   PubMed Web of Science ®Google Scholar
• Check JH, Wilson C, Cohen R, et al. Evidence that mifepristone, a progesterone receptor antagonist can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. Anticancer Res. 2014;34:2385–2388.
   PubMed Web of Science ®Google Scholar
• Check JH, Check D, Wilson C, et al. Long-term high-quality survival with single-agent mifepristone treatment despite advanced cancer. Anticancer Res. 2016;36:6511–6514.
   PubMed Web of Science ®Google Scholar
• Chien CH, Lai JN, Liso CF, et al. Mifepristone acts as progesterone antagonist of non-genomic responses but inhibits phytohemagglutinin-induced proliferation in human T cells. Hum Reprod. 2009;24:1968–1975.
   PubMed Web of Science ®Google Scholar
• Cohen RA, Check JH, Dougherty MP. Evidence that exposure to progesterone alone is a sufficient stimulus to cause a precipitous rise in the immunomodulatory protein the progesterone induced blocking factor (PIBF). J Assist Reprod Genet. 2016;33:221–229.
   PubMed Web of Science ®Google Scholar
• Check JH, DiAntonio G, DiAntonio A, et al. The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone. Clin Exp Obst Gynecol. 2016;43:189–191.
   PubMed Web of Science ®Google Scholar
• Ivanova-Todorova E, Kyurkchiev DS, Nalbanski A, et al. Production and characterization of a novel monoclonal antibody against progesterone-induced blocking factor (PIBF). J Reprod Immunol. 2008;78:94–101.
   PubMed Web of Science ®Google Scholar
• Check JH, Sarumi M, Diantonio A, et al. Serum levels of the progesterone induced blocking factor do not precipitously rise in women with gynecologic cancer in contrast to women exposed to progesterone. Clin Exp Obstet Gynecol. 2015;42:563–567.
   PubMed Web of Science ®Google Scholar
• Check JH, Rosenberg A, DiAntonio A, et al. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) are not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer. In: Proceedings of the American Association for Cancer Research; 2015 April 18-22. Philadelphia, PA: AACR; Clin Exp Obst Gynecol. 2017;44:187–189.
   Google Scholar
• Check JH, Dougherty MP, DiAntonio G, et al. Comparison of serum progesterone levels of the immunomodulatory protein, the progesterone induced blocking factor, in people with BRCA-2 mutations associated with and not associated with a high risk of cancer. In: Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia (PA): AACR; 2015. Abstract nr 1282.
   Google Scholar
• Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33(34):4093–4098.
   PubMed Web of Science ®Google Scholar
• Bertagna X, Escourolle H, Pinquier JL, et al. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab. 1994;78:375–380.
   PubMed Web of Science ®Google Scholar
• Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol. 2009;34(3):743–755.
   PubMed Web of Science ®Google Scholar
• Check JH, Nazari P, Goldberg J, et al. A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth. 2001;57:337–343.
   PubMed Web of Science ®Google Scholar
• Reyes HD, Carlson MJ, Devor EJ, et al. Downregulation of FOX01 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecol Oncol. 2016;140:152–160.
   PubMed Web of Science ®Google Scholar
• Kavlashvilli T, Jia Y, Dai D, et al. Inverse relationship between progesterone receptor and Myc in endometrial cancer. PLoS One. 2016;11(2):e0148912. DOI:10.1371/journal.pone.0148912
   Google Scholar